UK Drug Safety Update · April 30, 2026

Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse

Safety alert on rebound congestion and rhinitis medicamentosa risk with overuse of nasal decongestant sprays and drops containing xylometazoline or oxymetazoline.

Low obligation Product class Pharmaceuticals UK Pharmacovigilance

There have been reports of worsening nasal congestion (rebound congestion) when the effects of nasal decongestant sprays or drops containing xylometazoline hydrochloride and oxymetazoline hydrochloride, wear off.

Read the official source ↗

Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.